Table 3.
COVID-19 drugs used for treatment.
| 2020 (N = 39) | 2021 (N = 35) | 2022 (N = 106) | Total (N = 180) | |
|---|---|---|---|---|
| Drug | ||||
| Corticosteroids | 8 (20.5) | 7 (20) | 20 (18.9) | 35 (19.4) |
| Anti-inflammatory drugs* | 6 (15.4) | 6 (17.1) | 11 (10.4) | 23 (12.8) |
| Antiviral therapy | ||||
| Remdesivir | 11 (28.2) | 11 (31.4) | 24 (22.6) | 46 (25.6) |
| Molnupiravir | 0 (0.0) | 0 (0.0) | 1 (0.9) | 1 (0.6) |
| Nirmatrelvir/Ritonavir | 0 (0.0) | 0 (0.0) | 20 (11.1) | 20 (11.1) |
| Monoclonal antibodies | 0 (0.0) | 3 (8.6) | 15 (14.2) | 18 (10) |
| Convalescent plasma | 9 (23.1) | 8 (22.9) | 12 (11.3) | 29 (16.1) |
| Pre-exposure monoclonal antibodies | 0 (0.0) | 0 (0.0) | 4 (3.8) | 4 (2.2) |
*The given anti-inflammatory drugs were Tocilizumab, Siltuximab, Anakinra, Baricitinib and Eculizumab and no use of Ruxolitinib, Sarilumab or Colchicine was reported.